Agenus announces dividend of 5 million shares of mink therapeutics

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its board of directors has declared a dividend of 5 million shares of common stock of its subsidiary, mink therapeutics, inc. (“mink”), to shareholders of agenus as of april 17, 2023 (the “record date”).
AGEN Ratings Summary
AGEN Quant Ranking